A Deep Dive into the SGN-70 Antibody Vorsetuzumab represents a novel method in the field of oncology, specifically targeting the CD22 protein expressed on malignant blood cells. Developed by Seattle Genetics, it functions as an ADCC mechanism inducer, promoting natural removal of tumor cells. Studi